CHAPEL HILL, N.C., Dec 07, 2006 (BUSINESS WIRE) -- POZEN Inc. (NASDAQ:POZN) announced today that John R. Plachetka,
Pharm.D., the company's chairman, president & CEO, will participate in
the "House of Pain Relief" panel at the 2006 RBC Capital Markets
Healthcare Conference on Thursday, December 14, 2006 at 10:00 a.m.
(EST) at the New York Westin-Times Square in New York City. Dr.
Plachetka's presentation will be webcast and archived on POZEN's home
page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT technology, and
naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for proprietary fixed
dose combinations of the proton pump inhibitor esomeprazole magnesium
with naproxen in a single tablet for conditions such as osteoarthritis
and rheumatoid arthritis in patients who are at risk for developing
NSAID-associated gastric ulcers. The company's common stock is traded
on The Nasdaq Stock Market under the symbol "POZN". For detailed
company information, including copies of this and other press
releases, see POZEN's website: www.pozen.com.
SOURCE: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030
Fran Barsky, Director, Investor Relations, 919-913-1044